DNTH Stock Summary and Trading Ideas (Dianthus Therapeutics | NASDAQ:DNTH)

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Dianthus Therapeutics trades on the NASDAQ stock market under the symbol DNTH.

As of June 16, 2026, DNTH stock price declined to $78.88 with 735,487 million shares trading.

DNTH has a beta of 0.41, meaning it tends to be less sensitive to market movements. DNTH has a correlation of 0.01 to the broad based SPY ETF.

DNTH has a market cap of $4.31 billion. This is considered a Mid Cap stock.

Last quarter Dianthus Therapeutics reported $463,000 in Revenue and -$.85 earnings per share. This beat revenue expectation by $66,048 and exceeded earnings estimates by $.27.

The top ETF exchange traded funds that DNTH belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.

DNTH has outperformed the market in the last year with a return of +332.9%, while the SPY ETF gained +25.7%. However, in the most recent history, DNTH shares have underperformed the stock market with its stock returning +1.1% in the last 3 month period and -3.3% for the last 2 week period, while SPY has returned +12.4% and -1.2%, respectively.

DNTH support price is $78.81 and resistance is $86.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNTH shares will trade within this expected range on the day.